UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease: A Mini Review

Oxidative medicine and cellular longevity, 2016-01, Vol.2016 (1), p.8590578-8590578

2016

Volltextzugriff (PDF)

Multiple roles of HDAC inhibition in neurodegenerative conditions

Trends in neurosciences (Regular ed.), 2009-11, Vol.32 (11), p.591-601

2009

Volltextzugriff (PDF)

Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives

The Lancet (British edition), 2014-08, Vol.384 (9942), p.545-555

2014

Volltextzugriff (PDF)

The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases

International journal of molecular sciences, 2019-06, Vol.20 (12), p.3056

Maher, Pamela

2019

Volltextzugriff (PDF)

Dysregulation of glutathione homeostasis in neurodegenerative diseases

Nutrients, 2012-10, Vol.4 (10), p.1399-1440

2012

Volltextzugriff (PDF)

Suppression of Somatic Expansion Delays the Onset of Pathophysiology in a Mouse Model of Huntington's Disease

PLoS genetics, 2015-08, Vol.11 (8), p.e1005267

2015

Volltextzugriff (PDF)

Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial

Lancet neurology, 2015-01, Vol.14 (1), p.39-47

Anon

2015

Volltextzugriff (PDF)

Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

British journal of clinical pharmacology, 2013-02, Vol.75 (2), p.323-333

2013

Volltextzugriff (PDF)

Motor, cognitive, and functional declines contribute to a single progressive factor in early HD

Neurology, 2017-12, Vol.89 (24), p.2495-2502

2017

Volltextzugriff (PDF)

Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease

Drug design, development and therapy, 2018-01, Vol.12, p.313-319

2018

Volltextzugriff (PDF)

The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease

Neurobiology of disease, 2017-01, Vol.97 (Pt A), p.46-59

2017

Volltextzugriff (PDF)

Tetrabenazine for the Treatment of Hyperkinetic Movement Disorders: A Review of the Literature

Clinical therapeutics, 2012-07, Vol.34 (7), p.1487-1504

2012

Volltextzugriff (PDF)

Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease

Scientific reports, 2017-07, Vol.7 (1), p.5280-14, Article 5280

2017

Volltextzugriff (PDF)

Therapeutic Effect of Berberine on Huntington's Disease Transgenic Mouse Model

PloS one, 2015-07, Vol.10 (7), p.e0134142-e0134142

2015

Volltextzugriff (PDF)

Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation

Autophagy, 2024-05, Vol.20 (5), p.1159-1182

2024

Volltextzugriff (PDF)

An exploratory double‐blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease

British journal of clinical pharmacology, 2015-03, Vol.79 (3), p.465-476

2015

Volltextzugriff (PDF)

A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease

Journal of neuroinflammation, 2022-02, Vol.19 (1), p.56-56, Article 56

2022

Volltextzugriff (PDF)

Combination therapy with Coenzyme Q₁₀ and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's Diseases

Journal of neurochemistry, 2009-06, Vol.109 (5), p.1427-1439

2009

Volltextzugriff (PDF)

Neuroprotective effects of PPAR‐γ agonist rosiglitazone in N171‐82Q mouse model of Huntington's disease

Journal of neurochemistry, 2013-05, Vol.125 (3), p.410-419

2013

Volltextzugriff (PDF)

Discovery of a potent small molecule inhibiting Huntington's disease (HD) pathogenesis via targeting CAG repeats RNA and Poly Q protein

Scientific reports, 2019-11, Vol.9 (1), p.16872-15, Article 16872

2019

Volltextzugriff (PDF)

The mGluR5 positive allosteric modulator VU0409551 improves synaptic plasticity and memory of a mouse model of Huntington's disease

Journal of neurochemistry, 2018-10, Vol.147 (2), p.222-239

2018

Volltextzugriff (PDF)

Fragment-based virtual screening identifies a first-in-class preclinical drug candidate for Huntington's disease

Scientific reports, 2022-11, Vol.12 (1), p.19642-19642, Article 19642

2022

Volltextzugriff (PDF)

PARP-1 Inhibition Is Neuroprotective in the R6/2 Mouse Model of Huntington's Disease

PloS one, 2015-08, Vol.10 (8), p.e0134482-e0134482

2015

Volltextzugriff (PDF)

Neuroimmunology of Huntington’s Disease: Revisiting Evidence from Human Studies

Mediators of inflammation, 2016-01, Vol.2016, p.8653132-10

2016

Volltextzugriff (PDF)

The Sirtuin 2 Inhibitor AK-7 Is Neuroprotective in Huntington’s Disease Mouse Models

Cell reports (Cambridge), 2012-12, Vol.2 (6), p.1492-1497

2012

Volltextzugriff (PDF)

1 – 25 von 537

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(528)
Mit Volltextzugriff
(377)

Publikationsform

Artikel
(537)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Neurology
(73)
Plos One
(44)
International Journal Of Molecular Sciences
(31)
Neurobiology Of Disease
(27)
Journal Of Neurochemistry
(17)
Current Pharmaceutical Design
(15)
Current Drug Targets
(10)
Molecules
(10)
Molecules/molecules Online/molecules Annual
(10)
Scientific Reports
(10)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease: A Mini Review

Multiple roles of HDAC inhibition in neurodegenerative conditions

Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives

The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases

Dysregulation of glutathione homeostasis in neurodegenerative diseases

Suppression of Somatic Expansion Delays the Onset of Pathophysiology in a Mouse Model of Huntington's Disease

Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial

Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Motor, cognitive, and functional declines contribute to a single progressive factor in early HD

Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease

The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease

Tetrabenazine for the Treatment of Hyperkinetic Movement Disorders: A Review of the Literature

Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease

Therapeutic Effect of Berberine on Huntington's Disease Transgenic Mouse Model

Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation

An exploratory double‐blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease

A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease

Combination therapy with Coenzyme Q₁₀ and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's Diseases

Neuroprotective effects of PPAR‐γ agonist rosiglitazone in N171‐82Q mouse model of Huntington's disease

Discovery of a potent small molecule inhibiting Huntington's disease (HD) pathogenesis via targeting CAG repeats RNA and Poly Q protein

The mGluR5 positive allosteric modulator VU0409551 improves synaptic plasticity and memory of a mouse model of Huntington's disease

Fragment-based virtual screening identifies a first-in-class preclinical drug candidate for Huntington's disease

PARP-1 Inhibition Is Neuroprotective in the R6/2 Mouse Model of Huntington's Disease

Neuroimmunology of Huntington’s Disease: Revisiting Evidence from Human Studies

The Sirtuin 2 Inhibitor AK-7 Is Neuroprotective in Huntington’s Disease Mouse Models

Aktive Filter

Suchergebnisse filtern